BR112021020234A2 - Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1 - Google Patents

Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1

Info

Publication number
BR112021020234A2
BR112021020234A2 BR112021020234A BR112021020234A BR112021020234A2 BR 112021020234 A2 BR112021020234 A2 BR 112021020234A2 BR 112021020234 A BR112021020234 A BR 112021020234A BR 112021020234 A BR112021020234 A BR 112021020234A BR 112021020234 A2 BR112021020234 A2 BR 112021020234A2
Authority
BR
Brazil
Prior art keywords
glp
combination therapy
compounds
formula
receptor agonists
Prior art date
Application number
BR112021020234A
Other languages
English (en)
Inventor
Emeline Descamps
Robert Walczak
Vanessa Legry
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR112021020234A2 publication Critical patent/BR112021020234A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1. a presente invenção se refere a uma terapia de combinação que compreende um agonista de ppar e um agonista de receptor de glp-1.
BR112021020234A 2019-04-10 2020-04-09 Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1 BR112021020234A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305468 2019-04-10
PCT/EP2020/060283 WO2020208205A1 (en) 2019-04-10 2020-04-09 Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists

Publications (1)

Publication Number Publication Date
BR112021020234A2 true BR112021020234A2 (pt) 2021-12-07

Family

ID=66334312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020234A BR112021020234A2 (pt) 2019-04-10 2020-04-09 Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1

Country Status (10)

Country Link
US (1) US20220362187A1 (pt)
EP (1) EP3952855A1 (pt)
JP (1) JP2022528549A (pt)
KR (1) KR20210150436A (pt)
CN (1) CN113677336B (pt)
BR (1) BR112021020234A2 (pt)
CA (1) CA3130718A1 (pt)
MA (1) MA55592A (pt)
TW (1) TW202103694A (pt)
WO (1) WO2020208205A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113855812B (zh) * 2021-12-01 2022-03-11 上海翰森生物医药科技有限公司 聚乙二醇洛塞那肽或其药物组合物的新医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2504005B1 (en) * 2009-11-26 2013-11-06 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
WO2016112305A1 (en) * 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
TW201628625A (zh) * 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
US20180360846A1 (en) * 2015-09-16 2018-12-20 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN110087671A (zh) * 2016-12-22 2019-08-02 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
JP2020508316A (ja) * 2017-02-21 2020-03-19 ジェンフィＧｅｎｆｉｔ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor

Also Published As

Publication number Publication date
US20220362187A1 (en) 2022-11-17
CN113677336A (zh) 2021-11-19
WO2020208205A1 (en) 2020-10-15
CN113677336B (zh) 2024-04-30
EP3952855A1 (en) 2022-02-16
MA55592A (fr) 2022-02-16
JP2022528549A (ja) 2022-06-14
KR20210150436A (ko) 2021-12-10
TW202103694A (zh) 2021-02-01
CA3130718A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
ECSP21093576A (es) Agonistas del receptor del péptido-1 similar al glucagón
DOP2023000023A (es) Agonistas del glp-1 heterocíclicos
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
UY32350A (es) Régimen de dosificación de un agonista de los receptores de s1p
CR20110274A (es) Regimen de dosificacion para un agonista de los receptores de s1p
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
PH12020500655A1 (en) Compounds
BR112021024431A2 (pt) Inibidores da via de resposta ao estresse integrada
CL2022002105A1 (es) Agonistas heterocíclicos de glp-1
CL2016002809A1 (es) Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión.
CL2021001461A1 (es) Moduladores de trex1
CL2012000937A1 (es) Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
EA201692433A1 (ru) Соединения ppar для применения при лечении фиброзных заболеваний
CR20210607A (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
BR112017011883A2 (pt) composição de organosiloxano com alto índice de refração e aplicações contendo a mesma
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112021022378A2 (pt) Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo
BR112021020234A2 (pt) Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1
MA39337B1 (fr) Modulateurs de pyrazines de gpr6
MX2021004386A (es) Compuestos novedosos.
CY1123843T1 (el) Ρυθμιστες υποδοχεων α3 αδενοσινης
BR112022009765A2 (pt) Composição para inibir produção de hmf que compreende dissacarídeo de alulose